Actively Recruiting

Phase Not Applicable
Age: 50Years - 85Years
All Genders
NCT03671889

ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease

Led by InSightec · Updated on 2026-01-09

50

Participants Needed

10

Research Sites

587 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this study is to evaluate the safety and efficacy of the ExAblate Model 4000 Type 2.0 System as a tool to disrupt the blood-brain barrier (BBB) in patients with probable Alzheimer's Disease (AD).

CONDITIONS

Official Title

ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease

Who Can Participate

Age: 50Years - 85Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or Female between 50-85 years of age
  • Probable Alzheimer's Disease (AD)
  • If taking concurrent Alzheimer's medication, has been on the medication for at least 2 months with a stable dose for at least 3 months
  • Able to communicate sensations during the ExAblate MRgFUS procedure
  • Ambulatory
Not Eligible

You will not qualify if you...

  • MRI Findings
  • Presence of unknown or MR unsafe devices anywhere in the body
  • Significant cardiac disease or unstable hemodynamic status
  • Relative contraindications to ultrasound contrast agent or PET amyloid tracer
  • History of a bleeding disorder
  • History of liver disease
  • Known cerebral or systemic vasculopathy
  • Significant depression and at potential risk of suicide
  • Any contraindications to MRI scanning
  • Any contraindication to lumbar puncture for collection of cerebral spinal fluid
  • Untreated, uncontrolled sleep apnea
  • History of seizure disorder or epilepsy
  • Severely Impaired renal function
  • Currently in a clinical trial involving an investigational product or non-approved use of a drug or device or in any other type of medical research
  • Chronic pulmonary disorders
  • Positive human immunodeficiency virus (HIV)
  • Known apolipoprotein E allele (ApoE4) homozygosity

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 10 locations

1

Delray Medical Center & Florida Atlantic University

Delray Beach, Florida, United States, 33484

Actively Recruiting

2

Broward Health Medical Center & The University of Florida

Fort Lauderdale, Florida, United States, 33316

Actively Recruiting

3

University of Florida Health Shands

Gainesville, Florida, United States, 32608

Actively Recruiting

4

Baptist Health South Florida & Florida International University

Miami, Florida, United States, 33176

Actively Recruiting

5

Advent Health

Orlando, Florida, United States, 34747

Actively Recruiting

6

Tampa General Hospital

Tampa, Florida, United States, 33612

Actively Recruiting

7

Weill Cornell Medicine

New York, New York, United States, 10065

Active, Not Recruiting

8

The Ohio State University -Wexner Medical Center

Columbus, Ohio, United States, 43210

Active, Not Recruiting

9

University of Texas Southwestern Medical Center

Dallas, Texas, United States, 75390

Active, Not Recruiting

10

West Virginia University Rockefeller Neuroscience Center

Morgantown, West Virginia, United States, 26506

Active, Not Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SEQUENTIAL

Primary Purpose

DEVICE_FEASIBILITY

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease | DecenTrialz